New EU guidance clarifies the new notification obligation in case of interruption or discontinuation of supply of medical devices

Legal News
A Q&A from the European Commission addresses the new requirements of Article 10a of the MDR and IVDR regarding a notification obligation in case of interruption or discontinuation of the supply of medical devices and in vitro diagnostic devices.

In case of interruption or discontinuation of the supply of medical devices, the new Article 10a contains an obligation to inform the competent authority of the Member State. The information duty applies in the place where a manufacturer or its authorised representative is established, as well as the economic operators, health institutions and healthcare professionals to whom it directly supplies the device. This duty to inform only arises where it is reasonably foreseeable that such interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in one or more Member States. 

The new Article 10a of Regulation (EU) 2017/745 on medical devices ("MDR") and Regulation (EU) 2017/746 on in vitro medical devices ("IVDR") will apply from 10 January 2025, as defined in Article 3 of Regulation (EU)2024/1860 on the obligation to inform in case of interruption or discontinuation of supply etc.  

The European Commission recently published a Q&A concerning the practical aspects of the new information duty being implemented in both the MDR and IVDR. 

In the Q&A, the European Commission clarifies, among other things, when the notification obligation applies, what types of devices it covers, who is to be informed, and when the notification is to take place.

See the Q&A from the European Commission for further details or reach out to Plesner's Life Science team in case of questions. 

Q&A - Regulation (EU) 2024/1860 Article 10a MDR and IVDR